ACT Announces Europe's First Human Embryonic Stem Cell Transplant in Patient with Stargardt's Disease

January 2012
Biomedical Market Newsletter;1/28/2012, Vol. 21, p1
The article reports on an announcement made by Advanced Cell Technology Inc. (ACT) regarding first human embryonic stem cell transplant in a patient with Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells. According to Robert Lanza, chief scientific officer of ACT, stem cells provide the possibility of treatment of incurable retinal degenerative diseases. The RPE cells support, protect and provide nutrition for the light-sensitive photoreceptors.


Related Articles

  • No end in sight for stem-cell odyssey. Cyranoski, David // Nature;2/9/2006, Vol. 439 Issue 7077, p658 

    The article presents developments in the human embryonic stem-cell research of Advanced Cell Technology Corp. in Worcester, Massachusetts. In October 2003, Robert Lanza, vice-president for research says thirteen of sixteen cloned human eggs activated by transfer of a somatic nucleus had...

  • Stem cells derived without destruction of embryos. Bhojwani, Jyoti // Current Science (00113891);12/25/2006, Vol. 91 Issue 12, p1597 

    The article presents a letter which comments on the findings of a study by a research group from Advanced Cell Technology in Worcester, Massachusetts, led by Robert Lanza, which claimed that embryonic stem cells can be obtained for therapeutic use and other important applications without the...

  • CHOOSE LIFE. Singer, Peter; Sagan, Agata // Bulletin with Newsweek;9/5/2006, Vol. 124 Issue 6536, p36 

    The article focuses on the growing opposition against embryonic stem cell research. The successful development of embryonic stem cells without destroying the embryo by a team of scientists led by Robert Lanza at Massachusetts-based biotechnology firm Advanced Cell Technology Corp., has been...

  • RESEARCH & TECHNOLOGY.  // MondayMorning;11/23/2009, Vol. 17 Issue 45, p4 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) to use the investigational new drug application of human embryonic stem cells introduced by Advanced Cell Technology Inc. (ACT). The company and FDA have conducted a thorough review to determine its side effects...

  • Advanced Cell gets patent for hemangioblast cell generation.  // Medical Device Daily;9/20/2011, Vol. 15 Issue 179, p4 

    The article offers information on a patent received by Advanced Cell Technology (ACT) for its method of generating and expanding hemangioblast cells from human embryonic stem cells (hESCs). The company has an exclusive license for the commercialization of the technology in North America through...

  • Stem-cell research: Never say die. Lok, Corie // Nature;1/12/2012, Vol. 481 Issue 7380, p130 

    The article focuses on the research made by Advanced Cell Technology Inc. (ACT) and its chief scientific officer Robert Lanza on the implantation of retinal cells from human embryonic stem (ES) cells into the eye for treating blindness. It says that in 2004, Lanza and his team start testing the...

  • NIH Stem Cell Definition Change 'Hugely Important.'. Young, Donna // BioWorld Today;2/23/2010, Vol. 21 Issue 35, p4 

    The article focuses on the relevance of the proposal of the U.S. National Institute of Health to revise the definition of human embryonic stem cells (hESC) to include pluripotent cells derived from early stage human embryos, to Advanced Cell Technology Inc. (ACT). According to Robert Lanza,...

  • Simple protein helps human embryonic stem cells to thrive. Coghlan, Andy // New Scientist;1/19/2008, Vol. 197 Issue 2639, p13 

    This article reports that Robert Lanza of Advanced Cell Technology of Worcester, Massachusetts succeeded in creating human embryonic stem cells (hESCs) without destroying a human embryo in January, 2008 by adding laminin to blastomeres extracted from embryos.

  • Blind mice receive brand new light-sensing cells. Coghlan, Andy // New Scientist;7/27/2013, Vol. 219 Issue 2927, p11 

    The article reports on research published in "Nature Biotechnology" by scientist Robin Ali and team on the reversal of blindness in mice using immature light-sensing photoreceptors made from embryonic stem cells which self-organize, localize, and mature after transplantation into the eye.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics